Biosolution Co.,Ltd.
Financials
Valuation Metrics
Biosolution Co.,Ltd.'s Market Cap is ₩1377B. At end of 2025 it was ₩2051B. Ranked #1017 of 2,405 in KR market (top 42%), #512 of 1,627 on KOSDAQ (top 31%), #120 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 137.66B KRW | KR#1,017/2,405 Sec#120/231 |
| Revenue | 17.39B KRW | KR#2,172/2,405 Sec#161/231 |
| Net Income | 869.0M KRW | KR#1,488/2,405 Sec#102/231 |
| Total Assets | 66.27B KRW | KR#2,041/2,405 Sec#174/231 |
| Net Assets | 41.31B KRW | KR#2,022/2,405 Sec#177/231 |
| Employees | 88 | KR#1,736/2,405 Sec#138/231 |
| Value | ||
| P/E | 158.42x | KR#1,516/2,405 Sec#102/231 |
| P/B | 3.33x | KR#2,167/2,405 Sec#179/231 |
| P/S | 7.91x | KR#2,251/2,405 Sec#161/231 |
| FCF Yield | -1.09% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 2.10% | KR#1,396/2,405 Sec#96/231 |
| ROA | 1.31% | KR#1,350/2,405 Sec#97/231 |
| Op. Margin | -19.35% | KR#2,098/2,405 Sec#143/231 |
| Revenue Growth | 30.88% | KR#376/2,405 Sec#37/231 |
| Financial Health | ||
| Debt Ratio | 60.42% | KR#1,091/2,405 Sec#128/231 |
| Total Debt | 18.68B KRW | KR#1,395/2,405 Sec#112/231 |
| FCF | -1.50B KRW | KR#1,305/2,405 Sec#103/231 |
| Cash | 9.28B KRW | KR#1,731/2,405 Sec#150/231 |
| Current Ratio | 0.84x | KR#1,896/2,405 Sec#186/231 |
| Performance | ||
| 1Y Return | -34.04% | KR#1,562/2,405 Sec#125/231 |
| 1M Return | -20.75% | KR#1,916/2,405 Sec#187/231 |
| From 52W High | -60.52% | KR#1,687/2,405 Sec#141/231 |
| 1Y MDD | -59.00% | KR#1,380/2,405 Sec#115/231 |
| Trading | ||
| Volume | 25,333 shares | KR#1,372/2,405 Sec#130/231 |
| Trading Value | 134.5M KRW | KR#1,313/2,405 Sec#145/231 |
| Foreign Own. | 2.05% | KR#1,599/2,405 Sec#153/231 |
| Per Share | ||
| EPS | 34 KRW | KR#1,521/2,405 Sec#104/231 |
| BPS | 1,594 KRW | KR#2,172/2,405 Sec#186/231 |
Company Info
Established in 2000 as a cell therapy developer, the company changed its name in 2016, listed on KOSDAQ in 2018, and established local subsidiaries in China and Australia during the current period. It operates businesses in cell therapies, human stem cell-derived materials, peptide cosmetic ingredients, human tissue models, and alternative testing services. Following the commercialization of autologous cell therapies, the company is developing allogeneic cell therapies to expand commercialization and versatility. It is also expanding cosmetic ingredients through market expansion via human tissue model certification and joint research. BIOSOLUTIONS is headquartered in Nowon-gu, Seoul.